SynthesisJournal of nephrology2025
Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review.
Synthesis in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Potential Roles of Escherichia coli in IgA Nephropathy: Evidence, Mechanistic Hypotheses and Microbiota-Targeted Strategies.Microbial biotechnology · 2026Review
- Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.Clinical kidney journal · 2026Article
- A comparative study on the clinicopathological features and short-term prognosis of IgA-dominant infection-related glomerulonephritis and IgA nephropathy.BMC nephrology · 2026Article
- IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel, Switzerland) · 2026Review
- The role of mesenchymal stem cells in IgA nephropathy: current evidence and future directions.Stem cell research & therapy · 2026Review
- Timing of treatment-switch to telitacicept in high-risk IgA nephropathy: an observational case series of two clinical scenarios.BMC nephrology · 2026Observational
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
- Gut microbiota and gut-kidney axis in kidney diseases: therapeutic potential and perspectives of natural products.Frontiers in pharmacology · 2026Review
- Real-world multicenter evidence on Nefecon for attenuating proteinuria and kidney function decline in IgA nephropathy.Frontiers in immunology · 2026Observational
- Iptacopan in Patients With IgA Nephropathy From East Asia.Kidney international reports · 2026Article
- A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.Frontiers in medicine · 2025Article
- Advances in Complement-Targeted Therapy for IgA Nephropathy.Kidney diseases (Basel, Switzerland)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundIgA nephropathy (IgAN) is one of the most common primary glomerulonephritis worldwide, and its distribution varies significantly in different regions. The prevalence and trend of its changes in different regions of China are still unclear. Therefore, this study aims to analyze kidney biopsy data to summarize the prevalence and trend of IgAN in different regions in China.
methodsThrough a systematic electronic search of PubMed, Embase, China National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (SinoMed), Cochrane Library, and Wanfang databases from inception to March 1, 2023. Kidney biopsy data from the different provinces, municipalities and autonomous regions were recorded and analyzed.
resultsData concerning a total of 143,176 patients with primary glomerulonephritis in 34 provinces of China were extracted from the reported kidney biopsy data and included in the final analysis set, of which 39.73% were IgAN (56,886 cases). The proportions of male and female patients were 58.67% and 41.33%, respectively. The prevalence of IgAN patients was higher in economically developed provinces and municipalities. The weighted average prevalence before 2010 and after 2010 was 40.45% and 37.97%, respectively.
conclusionsIgAN remains the most common biopsy-proven primary glomerulonephritis in China. The prevalence of IgAN was 39.73% in China, and it was higher in developed provinces and municipalities than in other areas. The weighted average prevalence of IgAN in China decreased slightly after 2010.
Indexed as
Identifiers
40138167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.